March 7, 2019 | Michael Easterling
Australian lobster fisherman David Thompson traveled 9,000 miles for treatment at City of Hope after being diagnosed with Stage 4 oropharyngeal cancer. Given just six weeks to live, he is thriving more than a year after participating in an immunotherapy clinical trial.
First-of-its-kind CAR T clinical trial enrolls HER2+ breast cancer patients with brain metastases
October 30, 2018 | City of Hope
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
Groundbreaking new CAR T cell trial opens for patients with breast cancer that has spread to the brain
October 30, 2018 | Letisia Marquez
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
Parker Institute for Cancer Immunotherapy Welcomes Stephen J. Forman, M.D.
September 27, 2018 | Letisia Marquez
City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.
CAR T researcher Saul Priceman wants to teach your body to fight cancer
September 13, 2018 | Letisia Marquez
Since 2013, City of Hope researcher Saul Priceman, Ph.D., and his team have developed one of most comprehensive CAR T programs in the nation.
City of Hope's Stephen J. Forman Joins Parker Institute for Cancer Immunotherapy
July 16, 2018 | Letisia Marquez
City of Hope’s CAR T research and treatment team is now an official member of the Parker Institute for Cancer Immunotherapy.
CAR T Laboratory Research Yields Promising Prostate Cancer Results
April 17, 2018 | Letisia Marquez
City of Hope physicians have successfully treated blood cancers with chimeric antigen receptor (CAR) T cell therapy, and they are working to expand that therapy to patients with prostate cancer and other solid tumors.
With New CAR T Approach, City of Hope CEACAM Research Comes Full Circle
February 9, 2018 | Jyoti Madhusoodanan
CEA remains one of the most widely used clinical markers of cancer. As the diverse roles of CEA and CEACAMs, have grown clearer, researchers at City of Hope are working on a new wave of clinical tools and therapies.